Advanced Malignancy
22
2
2
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
4.5%
1 terminated out of 22 trials
94.1%
+7.6% vs benchmark
5%
1 trials in Phase 3/4
6%
1 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (22)
Immunotherapy Master Trial for Advanced Cancers
ADCX-020 for the Treatment of Patients With Locally Advanced or Metastatic Cancers
A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors
Clinical Efficacy of Transarterial Chemoembolization in Elderly Patients With Advanced Unresectable Colorectal Cancer
Changing the Paradigm of In-Hospital Cardiopulmonary Resuscitation
QUILT-2.014: Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas
Study of IBI318 in Participants With Advanced Malignancies
A Study of AMG 820 in Subjects With Advanced Solid Tumors
Safety Study of AMG 228 to Treat Solid Tumors
A Study of AMG 337 in Subjects With Advanced Solid Tumors
A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies
A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
A Study of Anlotinib in Subjects With Advanced Malignancy
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
QUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid Tumors
A Phase 1 Study of AMG 208 in Subjects With Advanced Solid Tumors
XL999 Administered Intravenously to a Subject With Advanced Malignancies